Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Toki-to (TKT) is a traditional Japanese Kampo (herbal) medicine investigated for its neuroprotective potential in the treatment of Parkinson's disease (PD). As a multi-component herbal decoction, it has demonstrated the ability to improve motor symptoms, such as bradykinesia, and protect dopaminergic neurons in the substantia nigra within animal models of PD. The drug's mechanism of action involves the suppression of **serum- and glucocorticoid-regulated kinase (SGK)** at the transcriptional level, a protein implicated in the pathogenesis of neurodegeneration. Additionally, Toki-to administration has been shown to reverse the downregulation of **tyrosine hydroxylase (TH)** and **dopamine transporter (DAT)** gene expression, thereby halting the progression of neurotoxicity and preserving dopaminergic function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on toki-to.